Gastrointestinal Diseases  >>  sofosbuvir/velpatasvir  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sofosbuvir/velpatasvir / Generic mfg.
ASTRAL-1, NCT02201940 / 2014-001683-35: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Checkmark DDW 2016 (ASTRAL-1)
Apr 2016 - Apr 2016: DDW 2016 (ASTRAL-1)
Checkmark ASTRAL-1, 2, 3 & 4 studies
Sep 2015 - Sep 2015: ASTRAL-1, 2, 3 & 4 studies
Completed
3
741
Canada, US, Europe, RoW
SOF/VEL, Epclusa®, GS-7977/GS-5816, Placebo
Gilead Sciences
Hepatitis C Virus Infection
06/15
09/15
ASTRAL-2, NCT02220998: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

Checkmark DDW 2016 (ASTRAL-2)
Apr 2016 - Apr 2016: DDW 2016 (ASTRAL-2)
Checkmark ASTRAL-1, 2, 3 & 4 studies
Sep 2015 - Sep 2015: ASTRAL-1, 2, 3 & 4 studies
Completed
3
269
US
SOF/VEL, Epclusa®, GS-7977/GS-5816, SOF, Sovaldi®, GS-7977, PSI-7977, RBV
Gilead Sciences
Hepatitis C Virus Infection
07/15
09/15
ASTRAL-4, NCT02201901: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

Checkmark ASTRAL-1, 2, 3 & 4 studies
Sep 2015 - Sep 2015: ASTRAL-1, 2, 3 & 4 studies
Completed
3
268
US
SOF/VEL, GS-7977/GS-5816, Epclusa®, RBV
Gilead Sciences
Hepatitis C Virus Infection
08/15
11/15
ASTRAL-3, NCT02201953 / 2014-001682-27: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Checkmark ASTRAL-1, 2, 3 & 4 studies
Sep 2015 - Sep 2015: ASTRAL-1, 2, 3 & 4 studies
Completed
3
558
Canada, US, Europe, RoW
SOF/VEL, Epclusa®, GS-7977/GS-5816, SOF, Sovaldi®, GS-7977, PSI-7977, RBV
Gilead Sciences
Hepatitis C Virus Infection
09/15
12/15
GS-US-342-1446, NCT02346721 / 2014-003898-42: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Completed
3
111
Canada, US, Europe, RoW
SOF/VEL, GS-7977/GS-5816, Epclusa®
Gilead Sciences
Hepatitis C Virus Infection
03/16
06/16
NCT02480712: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Completed
3
107
US
SOF/VEL, GS-7977/GS-5816, Epclusa®
Gilead Sciences
Hepatitis C Virus Infection
04/16
06/16
NCT02822794: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Completed
3
117
Japan
SOF/VEL, GS-7977/GS-5816, Epclusa®, RBV, REBETOL®
Gilead Sciences
Hepatitis C Virus Infection
06/17
08/17
GS-US-342-1522, NCT02722837 / 2015-003001-42: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Completed
3
119
Europe, RoW
SOF/VEL, GS-7977/GS-5816, Epclusa®
Gilead Sciences
Hepatitis C Virus Infection
06/17
09/17
GS-US-342-1518, NCT02671500: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Completed
3
375
RoW
SOF/VEL, GS-7977/GS-5816, Epclusa®
Gilead Sciences
Hepatitis C Virus Infection
01/18
03/18
GS-US-342-1521, NCT03074331: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Completed
3
130
RoW
SOF/VEL, Epclusa®, GS-7977/GS-5816
Gilead Sciences
Hepatitis C Virus Infection
02/18
02/18
NCT02996682: Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Completed
3
102
Japan
SOF/VEL, Epclusa®, RBV, Rebetol®
Gilead Sciences
Hepatitis C Virus Infection
02/18
05/18

Download Options